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complexity of the Association 
Between Psoriasis and comorbidities
Tamar Nijsten1 and Marlies Wakkee1
Multiple observational studies have recently demonstrated associations 
between psoriasis and several comorbidities—especially metabolic syndrome 
and cardiovascular disease, and now osteoporosis. It has been hypothesized 
that elevated levels of tumor necrosis factor-α are a biological explanation for 
the observed associations. In this commentary, we discuss the complexity of 
associations between psoriasis and comorbidities, possible residual confounding, 
the limitations of observational studies in proving causality, absolute versus rel-
ative risk differences, and the clinical relevance and possible clinical impact of 
“upgrading” psoriasis to a systemic disease.
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Several observational studies have 
recently demonstrated that psoriasis 
is associated with diseases other than 
psoriatic arthritis, including cardiovas-
cular disease and metabolic syndrome, 
cancer, chronic obstructive pulmonary 
disease, depression, and, in this issue, 
osteoporosis (Mallbris et al., 2004; 
Gelfand et al., 2006a,b; Dreiher et al., 
2008a,b). The trend in scientific litera-
ture and meeting presentations has been 
to “upgrade” psoriasis from a cutaneous 
to a systemic disease. But before we con-
sider accepting this hypothesis, which 
may have a considerable impact on the 
management of patients, the limitations 
of observational study designs and the 
available evidence should be reviewed.
complexity of association
The direct link between psoriasis and 
many of the possibly associated diseases 
is the presence of chronic inflammation 
and, in particular, elevated levels of the 
multifunctional cytokine tumor necrosis 
factor-α . However, several other factors 
may play important roles and confound 
this association (Figure 1). First, psoria-
sis has a major impact on patients’ lives 
and is associated with depressive symp-
toms in a relatively large proportion of 
patients (Stern et al., 2004). Impaired 
health-related quality of life (HRQOL) 
may lead to unhealthy lifestyle behav-
iors such as smoking, alcohol consump-
tion, decreased physical activity, and 
obesity, which are independent risk fac-
tors for many other diseases. Conversely, 
obesity and smoking may increase the 
risk of developing psoriasis (Naldi et al., 
2005; Setty et al., 2007), suggesting that 
these may be primary risk factors for 
several comorbidities and that psoriasis 
is no more than an innocent bystander. 
The presence of psoriatic arthritis may 
further limit patients’ physical function-
ing. In addition, psoriasis therapies (e.g., 
cyclosporine and prolonged topical 
steroid use) may increase the risk of sev-
eral comorbidities (e.g., cardiovascular 
risk and osteoporosis, respectively), and 
other drugs used to treat comorbidi-
ties may induce or exacerbate psoriasis 
(e.g., β-blockers and lithium). In addi-
tion to HRQOL impairment and (prior) 
drug exposure, several epidemiological 
biases may affect the association.
Most importantly, psoriasis patients 
are more likely to visit physicians 
because of their disease than “healthy” 
people from the general popula-
tion, which puts them at risk for being 
screened for and diagnosed with other 
diseases. This detection bias is especial-
ly important in the diagnosis of common 
diseases that are typically underdiag-
nosed, such as hypertension and osteo-
porosis in men (Dreiher et al., 2008a). 
Moreover, most psoriasis patients have 
limited disease (affecting less than one 
palm-sized area; Stern et al., 2004), 
and patients who seek medical care 
for their limited psoriasis are probably 
also more likely to seek care sooner for 
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other conditions. Diagnostic bias may 
be important in evaluating the associa-
tion between psoriasis and lymphomas 
(Gelfand et al., 2006b; Stern, 2006), 
because patients with cutaneous T-cell 
lymphoma (CTCL) may have initially 
been diagnosed with and registered as 
having psoriasis before their skin dis-
ease was diagnosed as CTCL, leading to 
a misclassification bias.
The detection of associations 
between psoriasis and comorbidities 
is challenging, because it has required 
the use of existing databases that were 
not designed for this purpose. Because 
the prevalence of most comorbidities 
is relatively low, large sample sizes are 
required to obtain sufficient power to 
test the associations. Therefore, health 
insurance data or existing large pro-
spective (national) cohort studies have 
been required to include a sufficient 
number of patients (often more than 
10,000 individuals). The limitation of 
these large datasets is that they usually 
have incomplete information—or none 
at all—about important confounders 
such as HRQOL, lifestyle factors, physi-
cal exercise, drug exposure, body mass 
index, and health-care consumption. 
Researchers may attempt to overcome 
these limitations by performing sub-
group analyses or by creating proxies 
for missing confounders. For example, 
health-care consumption may be rough-
ly estimated on the basis of number of 
drugs used or number of past diagno-
ses. The impact of including a proxy for 
health-care consumption is illustrated 
by the observation that, after adjusting 
for it, psoriasis patients were no longer 
significantly more likely to use cardio-
vascular drugs (Wakkee et al., 2008), 
and each additional diagnosis increased 
the risk of having osteoporosis by 
more than 20% (Dreiher et al., 2008a). 
Another example of the problem with 
using proxies in statistical models may 
be found in the osteoporosis study that 
assessed the role of decreased physical 
activity by hypothesizing that people 
with depression and/or blindness would 
be less likely to be physically active 
(Dreiher et al. 2008a). In fact, estimating 
physical activity is much more complex, 
and only a fraction of the actual level of 
physical activity may be ascertained in 
this way.
The observation by Dreiher et al. 
(2008a) that 56 of 100 diseases were 
associated with psoriasis raises the sus-
picion of residual confounding and the 
failure to address several biases. It is 
highly unlikely that psoriasis patients 
are at increased risk for developing 
the majority of these diseases com-
pared with patients without psoriasis. 
Although statistical multivariate mod-
els that adjust for available confound-
ers were used, 90% of the variability of 
the association between psoriasis and 
osteoporosis was not captured by the 
included covariates, confirming the 
presence of residual confounding (esti-
mated R square = 0.105).
absolute versus relative risk  
versus clinical relevance
The use of very large study popula-
tions increases the likelihood of detect-
ing statistically significant differences, 
because P-values depend on observed 
differences between cases and controls 
and on sample sizes. The absolute risk 
increment for developing comorbidities 
in psoriasis patients is almost always 
less than 5%. For example, the observed 
difference between patients and con-
trols for developing osteoporosis was 
less than 2.5% (3.1% vs. 1.7% for men 
and 22.3% vs. 20.2% for women), but 
because the study included almost 
8,000 patients, both differences were 
highly significant (p < 0.0001 and 
p = 0.008, respectively) (Dreiher et al. 
2008a). The absolute risk almost doubles 
in men, but in women it increases by 
only about one-tenth. After adjusting for 
age, inflammatory bowel disease, and a 
number of chronic conditions in a mul-
tivariate logistic model, the increased 
risk for men with psoriasis having osteo-
porosis decreased from about twofold 
to about 35% compared with controls 
(adjusted odds ratio = 1.35; 95% con-
fidence interval = 1.04–1.75), and the 
increased risk in women disappeared, 
despite the considerable residual con-
founding (Dreiher et al. 2008a).
The modest risk increments reported 
in this study should call into question 
their clinical relevance. Do the results 
of this study justify our classification of 
male psoriasis patients, without other 
risk factors, as being at high risk of 
developing osteoporosis, and should 
they receive bone mineral density scans? 
From this perspective, it would be inter-
esting to know the number of patients 
required to diagnose one additional 
|Statistical associations do not prove causality.
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Figure 1. Schematic overview of possible factors influencing the association between psoriasis and 
comorbidities. HRQOL, health-related quality of life.
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case of osteoporosis. The National 
Psoriasis Foundation advised physicians 
to adhere to the existing national guide-
lines for monitoring patients for cardio-
vascular disease and not to monitor all 
psoriasis patients independent of other 
risk factors. This recommendation is 
wise, because it reminds us that derma-
tologists are physicians who should look 
beyond the skin, it does not stigmatize 
psoriasis patients, and it acknowledges 
that causality has not yet been proved.
association versus causality
The strength of observational studies 
is in generating hypotheses, but their 
limitation is their inability to generate 
results that allow researchers to differ-
entiate clearly between association and 
causality. The likelihood of observing 
a causal relation increases when there 
is a clear biological explanation for 
the association, the association is con-
firmed in multiple studies, and there 
is a dose–response relationship and a 
clear temporal relationship between 
exposure and outcome. The increased 
inflammatory status of psoriasis patients 
with high levels of the multifunctional 
cytokine tumor necrosis factor-α is often 
proposed as the biological explanation 
for the association between psoriasis 
and several comorbidities, including 
osteoporosis. Multiple epidemiologi-
cal studies, but not all, have indicated 
that these patients are at increased risk 
for cardiovascular disease compared 
with the general population. Patients 
with moderate to severe psoriasis (i.e., 
patients who have used systemic drugs 
and/or have been hospitalized for psori-
asis) seem to be at higher risk for cardio-
vascular disease than patients with mild 
disease, indicating that there is a “dose–
response” relationship (Mallbris et al., 
2004; Gelfand et al., 2006a). Whether 
psoriasis precedes the comorbidities or 
vice versa is difficult to assess, but some 
risk factors for cardiovascular disease 
may induce or exacerbate psoriasis. For 
example, a prospective cohort study 
suggested that obese US nurses were 
at higher risk for developing psoriasis, 
and an Italian case–control study 
indicated that smoking may induce 
psoriasis (Naldi et al., 2005; Setty et al., 
2007). For other comorbidities, such as 
chronic obstructive pulmonary disease 
and osteoporosis, additional studies are 
warranted to confirm the recent find-
ings and to assess dose–response and 
temporal relationships before causal-
ity can be assumed. Ultimately, a need 
exists for large prospective cohorts that 
include incident psoriasis patients to 
confirm causality between psoriasis 
and other diseases.
Possible clinical impact
In contrast to other chronic inflam-
matory diseases such as rheumatoid 
arthritis, inflammatory bowel disease, 
and multiple sclerosis, cutaneous pso-
riasis does not progress to irrevers-
ible organ damage. Psoriasis often 
affects less than 3% of the body sur-
face area, waxes and wanes, and can 
often be treated topically, making it a 
relatively mild disease from a public 
health, scientific, and financial per-
spective. Because this view contrasts 
with patients’ perceptions, the derma-
tological community has embraced 
the “outcome movement”; by includ-
ing patient-reported outcomes such 
as HRQOL in the definition of disease 
severity, the proportion of psoriasis 
patients reported to have moderate to 
severe disease has increased consider-
ably. The measurement of the impact of 
psoriasis on patients’ lives may affect 
the allocation of limited resources and 
the management of psoriasis (via an 
increase in patient participation, the 
use of psychological counseling, con-
tinuous control of the disease, and, 
consequently, the use of systemic ther-
apies). “Upgrading” psoriasis to a sys-
temic disease may affect patient care in 
the long term by increasing adherence 
to existing screening guidelines for 
common internal diseases. However, 
it is also likely that in the near future, 
in line with current rheumatoid arthritis 
treatment, it will be suggested that more 
aggressive treatment of psoriasis may 
limit the clinical extent of the disease 
and/or decrease patients’ long-term 
risk of developing comorbidities such 
as cardiovascular disease. As noted 
above, before we accept this interesting 
and possibly important premise, more 
stringent clinical evidence should be 
weighed against other factors, such as 
clinical relevance and the risk–benefit 
ratios of therapies and costs.
conclusion
The ultimate question is whether statisti-
cally significant findings in observational 
studies indicate not only causality but 
also clinical relevance. Taking into con-
sideration the designs of studies, some 
inconsistencies in the findings, residual 
confounding, and the relatively mod-
est risk estimates, caution is warranted 
before psoriasis patients are screened 
and treated differently than other patients 
independent of other risk factors. Most 
importantly, the recent comorbidity stud-
ies reinforce the need to treat the whole 
patient, reminding dermatologists that 
they are physicians first—physicians with 
a special interest in skin.
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